In this interview, Gerald V. Naccarelli and Stephen D. Wiviott discuss the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Keywords: ACCELLite, ACC Annual Scientific Session, ACC19, AHA Annual Scientific Sessions, AHA18, Amputation, Atherosclerosis, Brain Ischemia, Diabetic Ketoacidosis, Diabetes Mellitus, Type 2, Dyslipidemias, Heart Failure, Glycated Hemoglobin A, Hyperglycemia, Hypertension, Metabolic Syndrome, Myocardial Infarction, Myocardial Ischemia, Primary Prevention, Renal Insufficiency, Chronic, Smoking, Stroke, Vascular Diseases

< Back to Listings